SAS and Carolina partner to accelerate antiviral drug development
Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI).
(UNC.edu)
Related: Campus Connections
Entrepreneur, UNC alum gives back, a bagel at a timeAlex Brandwein left UNC Kenan-Flagler Business School in May 2020 with two big accomplishments: an MBA and a lease for a bagel shop a few...
Tue Mar 17, 202620 years after seeds were distributed to children, Davie Poplar's legacy still grows
At nearly 400 years old, the Davie Poplar has stood on UNC-Chapel Hill’s campus for as long as the University has existed. But its legacy...
Mon Mar 16, 2026
UNC creative writing associate professor’s book earns national honor
One UNC faculty member’s newest book is earning accolades. “The New Economy,” written by Gabrielle Calvocoressi, has been named a finalist for the National Book...
Sat Mar 14, 2026
Carolina professor named FCC’s chief economist
Jonathan Williams is taking his economics expertise from the University of North Carolina to the federal government. Williams, a professor in the UNC College of...
Fri Mar 13, 2026
